Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists.

Auer E, Frey S, Kaesmacher J, Hakim A, Seiffge DJ, Goeldlin M, Arnold M, Fischer U, Jung S, Meinel TR.

J Neurol. 2019 Jun 4. doi: 10.1007/s00415-019-09412-y. [Epub ahead of print]

PMID:
31165232
2.

The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation.

Sakamoto Y, Okubo S, Nito C, Suda S, Matsumoto N, Abe A, Aoki J, Shimoyama T, Takayama Y, Suzuki K, Mishina M, Kimura K.

Eur J Neurol. 2017 Nov;24(11):1399-1406. doi: 10.1111/ene.13405. Epub 2017 Sep 5.

PMID:
28799181
3.

Effect of direct oral anticoagulant for acute major cerebral artery occlusion in cardioembolic stroke/transient ischemic attack patients with non-valvular atrial fibrillation.

Tomari S, Arima J, Yoshida T, Yamashita H, Sata R, Hamada R, Kanda N, Takashima H.

J Neurol Sci. 2019 Jul 15;402:162-166. doi: 10.1016/j.jns.2019.05.023. Epub 2019 May 23.

PMID:
31152970
4.

Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation.

Benzimra M, Bonnamour B, Duracinsky M, Lalanne C, Aubert JP, Chassany O, Aubin-Auger I, Mahé I.

Patient Prefer Adherence. 2018 Jan 4;12:79-87. doi: 10.2147/PPA.S131158. eCollection 2018.

5.

Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.

Anguita Sánchez M, Bertomeu Martínez V, Ruiz Ortiz M, Cequier Fillat Á, Roldán Rabadán I, Muñiz García J, Badimón Maestro L, Esteve Pastor MA, Marín Ortuño F; FANTASIIA study investigators.

Rev Esp Cardiol (Engl Ed). 2019 May 31. pii: S1885-5857(19)30120-3. doi: 10.1016/j.rec.2019.02.021. [Epub ahead of print] English, Spanish.

PMID:
31160265
6.

The neurologist's approach to cerebral infarct and transient ischaemic attack in patients receiving anticoagulant treatment for non-valvular atrial fibrillation: ANITA-FA study.

Zapata-Wainberg G, Masjuan J, Quintas S, Ximénez-Carrillo Á, García Pastor A, Martínez Zabaleta M, Cardona P, Freijo Guerrero MM, Llull L, Benavente Fernández L, Castellanos Rodrigo M, Egido J, Serena J, Vivancos J; researchers in the ANITA-FA study.

Eur J Neurol. 2019 Feb;26(2):230-237. doi: 10.1111/ene.13792. Epub 2018 Sep 24.

PMID:
30153363
7.

Prescription frequency and predictors for the use of novel direct oral anticoagulants for secondary stroke prevention in the first year after their marketing in Europe--a multicentric evaluation.

Luger S, Hohmann C, Kraft P, Halmer R, Gunreben I, Neumann-Haefelin T, Kleinschnitz C, Walter S, Haripyan V, Steinmetz H, Foerch C, Pfeilschifter W.

Int J Stroke. 2014 Jul;9(5):569-75. doi: 10.1111/ijs.12289. Epub 2014 May 15.

PMID:
24828272
8.

Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage.

Tsivgoulis G, Lioutas VA, Varelas P, Katsanos AH, Goyal N, Mikulik R, Barlinn K, Krogias C, Sharma VK, Vadikolias K, Dardiotis E, Karapanayiotides T, Pappa A, Zompola C, Triantafyllou S, Kargiotis O, Ioakeimidis M, Giannopoulos S, Kerro A, Tsantes A, Mehta C, Jones M, Schroeder C, Norton C, Bonakis A, Chang J, Alexandrov AW, Mitsias P, Alexandrov AV.

Neurology. 2017 Sep 12;89(11):1142-1151. doi: 10.1212/WNL.0000000000004362. Epub 2017 Aug 16. Review.

PMID:
28814457
9.

Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation.

Seiffge DJ, Paciaroni M, Wilson D, Koga M, Macha K, Cappellari M, Schaedelin S, Shakeshaft C, Takagi M, Tsivgoulis G, Bonetti B, Kallmünzer B, Arihiro S, Alberti A, Polymeris AA, Ambler G, Yoshimura S, Venti M, Bonati LH, Muir KW, Yamagami H, Thilemann S, Altavilla R, Peters N, Inoue M, Bobinger T, Agnelli G, Brown MM, Sato S, Acciarresi M, Jager HR, Bovi P, Schwab S, Lyrer P, Caso V, Toyoda K, Werring DJ, Engelter ST, De Marchis GM; CROMIS-2, RAF, RAF-DOAC, SAMURAI, NOACISP LONGTERM, Erlangen and Verona registry collaborators.

Ann Neurol. 2019 Jun;85(6):823-834. doi: 10.1002/ana.25489. Epub 2019 Apr 30.

10.

Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: A systematic review and meta-analysis.

Hellfritzsch M, Adelborg K, Damkier P, Paaske Johnsen S, Hallas J, Pottegård A, Lerkevang Grove E.

Basic Clin Pharmacol Toxicol. 2019 Jun 25. doi: 10.1111/bcpt.13283. [Epub ahead of print] Review.

PMID:
31240841
11.

Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.

Brinkmeier-Theofanopoulou M, Tzamalis P, Wehrkamp-Richter S, Radzewitz A, Merkel M, Schymik G, van Mark G, Bramlage P, Schmitt C, Luik A.

BMC Cardiovasc Disord. 2018 Apr 27;18(1):71. doi: 10.1186/s12872-018-0804-6.

12.

Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation.

Sakamoto Y, Okubo S, Sekine T, Nito C, Suda S, Matsumoto N, Nishiyama Y, Aoki J, Shimoyama T, Kanamaru T, Suzuki K, Mishina M, Kimura K.

J Am Heart Assoc. 2018 Sep 4;7(17):e009507. doi: 10.1161/JAHA.118.009507.

13.

Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.

Ha FJ, Barra S, Brown AJ, Begley DA, Grace AA, Agarwal S.

Int J Cardiol. 2018 Jul 1;262:51-56. doi: 10.1016/j.ijcard.2018.03.095. Epub 2018 Mar 21. Review.

PMID:
29606512
14.
15.

Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.

Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C.

Semin Thromb Hemost. 2014 Feb;40(1):121-8. doi: 10.1055/s-0033-1361940. Epub 2013 Dec 31.

16.

Insufficient Warfarin Therapy Is Associated With Higher Severity of Stroke Than No Anticoagulation in Patients With Atrial Fibrillation and Acute Anterior-Circulation Stroke.

Sakamoto Y, Okubo S, Nito C, Suda S, Matsumoto N, Nishiyama Y, Aoki J, Shimoyama T, Kanamaru T, Suzuki K, Mishina M, Kimura K.

Circ J. 2018 Apr 25;82(5):1437-1442. doi: 10.1253/circj.CJ-17-1110. Epub 2017 Dec 21.

17.

Cognitive impairment is not a predictor of failure to adhere to anticoagulation of stroke patients with atrial fibrillation.

Horstmann S, Rizos T, Saribas M, Efthymiou E, Rauch G, Veltkamp R.

Cerebrovasc Dis. 2015;39(5-6):325-31. doi: 10.1159/000381728. Epub 2015 May 7.

18.

Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events.

Seiffge DJ, Traenka C, Polymeris A, Hert L, Peters N, Lyrer P, Engelter ST, Bonati LH, De Marchis GM.

Neurology. 2016 Nov 1;87(18):1856-1862. Epub 2016 Sep 30.

PMID:
27694266
19.

Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism.

Keita I, Aubin-Auger I, Lalanne C, Aubert JP, Chassany O, Duracinsky M, Mahé I.

Patient Prefer Adherence. 2017 Sep 25;11:1625-1634. doi: 10.2147/PPA.S131157. eCollection 2017.

20.

Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.

Sindet-Pedersen C, Lamberts M, Staerk L, Nissen Bonde A, Berger JS, Pallisgaard JL, Lock Hansen M, Torp-Pedersen C, Gislason GH, Olesen JB.

J Am Coll Cardiol. 2018 Oct 9;72(15):1790-1800. doi: 10.1016/j.jacc.2018.07.054.

PMID:
30286922

Supplemental Content

Support Center